20% of profits go to charity
Ogovy is part of the Medstack Ltd family alongside Monj and iGovy. Across the network we commit at least 20 percent of relevant profits to UK charities, and we keep a public, verifiable record of where that support has gone.
Why we give
Ogovy exists to make private treatment pricing honest and easy to compare. If that work builds a successful business, we think part of the benefit should travel further than the business itself. Giving is part of how the network is run. We don’t treat it as a year-end marketing exercise.
The active donation record
The network keeps one public list of every charity that Monj, iGovy, Ogovy or Medstack Ltd has donated to or financially supported. It is a record of support already provided, not a wish list, and each entry links to the charity itself and its Charity Commission record so the details can be checked independently.
How the pledge works
A charity is only added to the record after a donation or financial support has been given. Charities do not pay to appear, are not asked for promotion or referrals in return, and inclusion does not mean a charity endorses Ogovy, Medstack Ltd, any pharmacy, treatment or medicine. We keep the comparison service and the charity record separate. One helps you check prices and providers. The other shows where part of the profit has gone.
Who stands behind the pledge
Ogovy is operated by Medstack Ltd, registered in England and Wales, company number 16439872. The same pledge covers the whole network: Monj for Mounjaro comparison, iGovy for Wegovy pen comparison and Ogovy for oral treatment comparison. Separately from the pledge, Ogovy also highlights EveryDoctor, whose work supports a properly funded NHS and safer patient care.
Sources referenced on this page
Linked from the text above:
- company number 16439872 find-and-update.company-information.service.gov.uk
Standing primary references for every Ogovy page:
- Wegovy (semaglutide) Summary of Product Characteristics and Patient Information Leaflet, electronic medicines compendium
- MHRA Drug Safety Update: GLP-1 receptor agonists
- NICE TA875: semaglutide for managing overweight and obesity
- General Pharmaceutical Council register of pharmacies
- MHRA Yellow Card scheme

